ODDITY Tech (NASDAQ:ODD) 株価情報

ODDITY Tech

ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.

ODDITY Tech Ltd. - Class A Ordinary Shares

ODDITY Tech Ltd

ODD BURGER CORPORATION by Odd Burger Corporation

Odd Burger Corp

Pacer BlueStar Digital Entertainment ETF

Oddz

Throughout the last three months, 13 analysts have evaluated Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $129.46, a high estimate of $140.00, and a low estimate of $119.00. This upward trend is evident, with the current average reflecting a 0.12% increase from the previous average price target of $129.31.
<img src="https://www.benzinga.com/files/images/story/2025/1741039255_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Blueprint Medicines by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reni Benjamin</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Blueprint Medicines's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Blueprint Medicines's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
<h3>Breaking Down Blueprint Medicines's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Blueprint Medicines displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 103.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Blueprint Medicines's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -34.13%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -16.33%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Blueprint Medicines's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Blueprint Medicines's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BPMC

13 Analysts Assess Blueprint Medicines: What You Need To Know

In the preceding three months, 6 analysts have released ratings for Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.67, a high estimate of $23.00, and a low estimate of $16.00. Observing a 8.74% increase, the current average has risen from the previous average price target of $17.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1741039245_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Crescent Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crescent Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Crescent Energy compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Crescent Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Crescent Energy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRGY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crescent Energy analyst ratings.</a>
<h2>All You Need to Know About Crescent Energy</h2>
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
<h3>Understanding the Numbers: Crescent Energy's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Crescent Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 33.08% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Crescent Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crescent Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Crescent Energy's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.28%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Crescent Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGY

A Glimpse Into The Expert Outlook On Crescent Energy Through 6 Analysts

Ecovyst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECVT#NYSE">ECVT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.5, a high estimate of $12.00, and a low estimate of $9.00. Highlighting a 2.33% decrease, the current average has fallen from the previous average price target of $10.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741039236_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Ecovyst is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ecovyst. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ecovyst compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ecovyst's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ecovyst's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ECVT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ecovyst analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Ecovyst's Background</h2>
Ecovyst Inc is a integrated and global provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: (1) Ecoservices and (2) Advanced Materials &amp; Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
<h3>Ecovyst: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Ecovyst's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 5.3%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ecovyst's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -16.72%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ecovyst's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.25%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ecovyst's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.67%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ecovyst's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.28, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ECVT

4 Analysts Have This To Say About Ecovyst

In the latest quarter, 8 analysts provided ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $12.88, a high estimate of $16.00, and a low estimate of $11.50. Surpassing the previous average price target of $12.62, the current average has increased by 2.06%.
<img src="https://www.benzinga.com/files/images/story/2025/1741039222_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teladoc Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Teladoc Health's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -7.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.37%, the company showcases effective utilization of assets.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TDOC

Where Teladoc Health Stands With Analysts

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) has outperformed the market over the past 10 years by 22.48% on an annualized basis producing an average annual return of 33.52%. Currently, HubSpot has a market capitalization of $36.91 billion. 
Buying $100 In HUBS: If an investor had bought $100 of HUBS stock 10 years ago, it would be worth $1,801.96 today based on a price of $707.63 for HUBS at the time of writing.
<h3>HubSpot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741039214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

HUBS

Here's How Much You Would Have Made Owning HubSpot Stock In The Last 10 Years

The consolidation of Videology operations is being undertaken to increase efficiencies and lower operating costs associated with the current operation of Videology.&nbsp;
The consolidation is expected to be substantially completed by the end of 2025 at which point the Company intends to fully vacate the Netherlands facility.
As a result of this action, the Company expects to incur cash charges for severance and other one-time termination benefits of $350,000.&nbsp;
In addition, the Company expects to incur cash charges for other costs related to the facility consolidation, including moving costs, costs associated with the termination of the Netherlands facility lease and other consolidation costs, ranging from $200,000 to $300,000.

INTT

inTEST Intends To Consolidate All Videology Operations In The Netherlands Into Facility In Mansfield, Massachusetts; Plan Would Result In Closure Of  Netherlands Facility And Termination Of Certain Employees At That Location - Filing

Citigroup analyst Asiya Merchant maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Neutral and lowers the price target from $135 to $110.

Price Target

NTAP

Citigroup Maintains Neutral on NetApp, Lowers Price Target to $110

Quantum-Si Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/03/b44093920/quantum-si-reports-fourth-quarter-and-full-year-2024-financial-results">figures from the report. </a>
The Details:&nbsp;Quantum-Si reported quarterly losses of&nbsp;23 cents&nbsp;per share which missed the analyst consensus estimate of&nbsp;a loss of 19 cents. Quarterly revenue came in at $1.19 million&nbsp;which missed the analyst consensus estimate of&nbsp;$1.23 million&nbsp;and is an&nbsp;increase over revenue of $400,000 from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44084997/tesla-rebounds-while-tariffs-weigh-on-manufacturing-whats-driving-markets-monday">Tesla Rebounds While Tariffs Weigh On Manufacturing: What&#8217;s Driving Markets Monday?</a>
&#8220;I am very pleased with how we closed out 2024, delivering our first quarter in excess of $1 million in revenue, the launch of our version 2 Library Preparation Kit and our new Barcoding Kit. We also had a very successful investor and analyst day where we showcased our technology roadmap and announced our next generation Proteus development program and related commercial and development partnerships,&#8221; said Jeff Hawkins, CEO of Quantum-Si.
Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Quantum-Si shares are up 3.83% after hours at $1.35 Monday.  
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image: Courtesy of Quantum-Si, Inc.

Earnings

Movers

Tech

Quantum-Si Shares Climb Despite Worse-Than-Expected Q4 Results

Barclays analyst Lauren Lieberman maintains Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) with a Overweight and raises the price target from $19 to $23.

NOMD

Barclays Maintains Overweight on Nomad Foods, Raises Price Target to $23

"As we progress through 2025 with a stronger balance sheet, we remain poised to take advantage of potential acquisitions that will be accretive to our stakeholders. We remain committed to enhancing shareholder value and returning value to our shareholders through the quarterly dividend in place since November 2023," the company said.

Guidance

W&T Offshore Expects Capital Expenditure Budget For 2025 Of $34M - $42M

Leerink Partners analyst Faisal Khurshid downgrades Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Outperform to Market Perform and lowers the price target from $33 to $2.

Downgrades

PLRX

Leerink Partners Downgrades Pliant Therapeutics to Market Perform, Lowers Price Target to $2

W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 200 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $120.34 million which missed the analyst consensus estimate of $126.09 million by 4.56 percent. This is a 9.06 percent decrease over sales of $132.34 million the same period last year.

Earnings Misses

W&T Offshore Q4 2024 Adj EPS $(0.18) Misses $(0.14) Estimate, Sales $120.34M Miss $126.09M Estimate

JP Morgan analyst Mark Strouse downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Overweight to Neutral.

NOVA

JP Morgan Downgrades Sunnova Energy Intl to Neutral

CTHR

Charles & Colvard Reveals Receipt Of Nasdaq Notice Regarding Delayed Form 10-Q

The notes will be guaranteed on a senior unsecured basis by Alcoa and certain of its subsidiaries. The sale of the notes is expected to be completed on March 17, 2025, subject to customary closing conditions.

Offerings

Alcoa Subsidiary Prices Offering Of $1B Of Senior Notes

BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) has outperformed the market over the past 20 years by 5.12% on an annualized basis producing an average annual return of 13.29%. Currently, BlackRock has a market capitalization of $150.19 billion. 
Buying $1000 In BLK: If an investor had bought $1000 of BLK stock 20 years ago, it would be worth $11,998.39 today based on a price of $967.37 for BLK at the time of writing.
<h3>BlackRock's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741038309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Janney Montgomery Scott analyst Daniel Cardenas upgrades ChoiceOne Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COFS#NASDAQ">COFS</a>) from Neutral to Buy.

Upgrades

COFS

Janney Montgomery Scott Upgrades ChoiceOne Finl Servs to Buy

Management

Origin Bancorp Says Five Members Of Its Board Will Not Stand For Reelection At 2025 Annual Meeting Of Stockholders, Decreasing Size Of Board From 16 To 11 Directors

The dividend is payable on May 9, 2025, to shareholders of record on April 4, 2025.

Dividends

American Express Boosts Quarterly Dividend By 17% From $0.70 To $0.82 Per Share

GigaCloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/03/g44093898/gigacloud-technology-inc-announces-fourth-quarter-and-year-ended-december-31-2024-financial-result">details from the report</a>.
The Details:&nbsp;GigaCloud Technology reported quarterly earnings of&nbsp;75&nbsp;cents per share which missed the analyst consensus estimate of&nbsp;81&nbsp;cents. Quarterly revenue came in at&nbsp;$295.78 million&nbsp;which beat the analyst consensus estimate of&nbsp;$288.33 million and is an&nbsp;increase over revenue of&nbsp;$244.73 million&nbsp;from the same period last year.
The company also reported: 
<ul>
<li>Gross profit of $65 million, decreased 6.9% year-over-year.</li>
<li>Gross margin was 22%, compared to 28.5% in the fourth quarter of 2023.</li>
<li>GigaCloud Marketplace GMV3 increased 68.9% year-over-year to $1.34 billion for the 12 months ended Dec. 31, 2024.</li>
<li>Spend per active buyer was $144,142 for the 12 months ended Dec. 31, 2024.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44084997/tesla-rebounds-while-tariffs-weigh-on-manufacturing-whats-driving-markets-monday">Tesla Rebounds While Tariffs Weigh On Manufacturing: What&#8217;s Driving Markets Monday?</a>
The El Monte, California-based company also announced its board of directors approved the appointment of Erica Wei as chief financial officer after serving as interim CFO since August 2024.
&#8220;2024 was a landmark year for GigaCloud as we surpassed $1 billion in total revenues for the first time, a milestone that underscores the strength and resilience of our B2B Marketplace amid a challenging macroeconomic environment,&#8221; said Larry Wu, CEO. 
Outlook:&nbsp;The company sees&nbsp;first-quarter revenue in a range of&nbsp;$250 million to $265 million, versus the&nbsp;$281.4 million&nbsp;analyst estimate.
GCT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, GigaCloud Technology shares are down 8.55% after hours at $14.65 after dropping 5.38% during Monday&#8217;s regular trading session.&nbsp;&nbsp;
Read Next:<a href="https://www.benzinga.com/government/regulations/25/02/43903335/financial-crime-weekly-1-4-billion-ethereum-stolen-in-largest-crypto-hack-ever-sec-creates-cyber-and-emerging-technologies-unit">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image: Shutterstock&nbsp;

GigaCloud Technology Stock Drops After Q4 Results: Here's Why

Press Releases

Faruqi & Faruqi Reminds Oddity Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 17, 2024 - ODD

Legal

ODD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ODDITY Tech Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ODDITY Tech Ltd. of Class Action Lawsuit and Upcoming Deadlines - ODD

Comments

ODDITY Tech

ニュース

パートナーシップ

ベンジンガ・グローバル